咖啡愛好者鬆了一口氣了（咖啡和死亡率的關係）

ORIGINAL RESEARCH |11 JULY 2017

Coffee Drinking and Mortality in 10 European Countries: A Multinational Cohort Study

http://annals.org/aim/article/2643435/coffee-drinking-mortality-10-european-countries-multinational-cohort-study

ORIGINAL RESEARCH |11 JULY 2017

Association of Coffee Consumption With Total and Cause-Specific Mortality Among Nonwhite Populations

http://annals.org/aim/article/2643433/association-coffee-consumption-total-cause-specific-mortality-among-nonwhite-populations

這一期的Annal of Internal Medicine，給咖啡愛好者鬆了一口氣，因為有2篇大型並且長期研究（52萬人橫越10個歐洲國家，平均16年追蹤）（另一篇18.5萬人，非白人，16年追蹤），都顯示咖啡可以減少死亡率。

雖然這不是新聞，但是這是有史以來最大的研究。而且，不管是抽煙者或是非抽煙者，喝咖啡都會減少死亡率 。並且，對於腎臟、心血管、或是其他內臟疾病都有減少發生率。

今日最中肯，作者：
"I think that the solid conclusion is that if you're a coffee drinker, keep drinking your coffee and be happy," Ascherio said. And if you're not? "I think you can go on drinking your tea or water without a problem."

"The takeaway message would be that drinking a couple cups of coffee a day doesn't do you any harm, and actually, it might be doing you some good," he said.

以下是CNN的報導
http://edition.cnn.com/2017/07/10/health/coffee-leads-to-longer-life-studies-reaffirm/index.html

FDA: Restricting MRI Contrast Agents "Not Warranted"

當住院醫師時，腎臟病人要做檢查要儘量避免有顯影劑的CT，最好是做MRI因為不傷腎。當FELLOW時，腎臟病人儘量不要做顯影劑CT，最好也不要做MRI(因為使用gadolinium，有少數報告說會造成nephrogenic systemic fibrosis）。

10多年後，FDA說，MRI 用的gadolinium顯影劑沒有那麼多副作用，不需要限制使用。

Science is forever changing！

May 24, 2017
FDA: Restricting MRI Contrast Agents "Not Warranted"
By Kristin J. Kelley NEJM JOURNAL WATCH

Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM

There isn't evidence to warrant restricting the use of gadolinium-based contrast agents (GBCAs), the IV drugs used during magnetic resonance imaging, the FDA has concluded.

The agency began evaluating the risk for adverse health events associated with the heavy metal gadolinium retained in the brain after multiple uses of GBCAs. Reports showed that while gadolinium is retained in the body (including the brain, bones, and skin), no adverse health effects were found to be associated with the retention, apart from a rare condition known as nephrogenic systemic fibrosis.

The safety of GBCAs will continue to be investigated by conducting more research, including studies on how gadolinium is retained in the body. Clinicians should follow the FDA recommendations issued in 2015.

https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm